[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556453":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":42,"centralContacts":47,"locations":53,"responsibleParty":72,"collaborators":11,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":11,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":11,"enrollmentInfo":83,"targetDuration":11,"studyType":86,"phases":87,"briefSummary":90,"conditions":91,"keywords":11,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Eisbach Bio GmbH","INDUSTRY",[8,14,17,22],{"label":9,"type":10,"description":11,"interventionNames":12},"EIS-12656 Dose Escalation","EXPERIMENTAL",null,[13],"Drug: EIS-12656",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose Expansion Module 1 (EIS-12656 Monotherapy)",[13],{"label":18,"type":10,"description":19,"interventionNames":20},"Dose Expansion Module 2 (EIS-12656 + Olaparib)","EIS-12656 will be given in combination with Olaparib",[13,21],"Drug: Olaparib",{"label":23,"type":10,"description":24,"interventionNames":25},"Dose Expansion Module 3 (EIS-12656 + T-DXd)","EIS-12656 will be given in combination with Trastuzumab deruxtecan",[13,26],"Drug: Trastuzumab deruxtecan",[28,33,37],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","EIS-12656","EIS-12656 tablets given daily",[15,18,23,9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"Olaparib","as per USPI\u002FSmPC",[18],{"type":29,"name":38,"description":35,"armGroupLabels":39,"otherNames":40},"Trastuzumab deruxtecan",[23],[41],"Enhertu",[43],{"name":44,"affiliation":45,"role":46},"Timothy Yap","M.D. Anderson Cancer Center","PRINCIPAL_INVESTIGATOR",[48],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},"Adrian Schomburg","CONTACT","+49 17621046886","adrian@eisbach.bio",[54],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-95.36327,29.76328,{"lat":66,"lon":65},[69],{"name":44,"role":50,"phone":70,"phoneExt":11,"email":71},"713-563-1784","TYap@mdanderson.org",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100556453","phase-1-eis-12656-as-single-agent-and-in-combination-in-patients-with-specified-solid-tumors-100556453",false,"NCT06525298","EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","A Phase 1\u002F2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors","Inclusion Criteria:\n\n* Recurrent locally advanced or metastatic solid tumors\n* Homologous recombination deficient mutations\n* Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy\n* Measurable disease (RECIST 1.1 Criteria)\n* Adequate organ and bone marrow function\n* ECOG Performance Status 0 or 1\n* Life expectancy \\> 3 months\n\nExclusion Criteria:\n\n* History or evidence of any clinically relevant gastrointestinal disease\n* Radiation therapy within ≤2 weeks\n* Significant cardiovascular disease\n* Uncontrolled, active, symptomatic brain metastases","ALL","18 Years",{"count":84,"type":85},144,"ESTIMATED","INTERVENTIONAL",[88,89],"PHASE1","PHASE2","This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).",[92,93,94],"Advanced Solid Tumor","Homologous Recombination Deficiency","HRR Deficiency","2024-09-14",{"date":97,"type":98},"2024-09-19","ACTUAL",{"date":100,"type":98},"2024-09-09",{"date":102,"type":85},"2027-12",{"name":5,"class":6},1]